According to a recent LinkedIn post from KROMATID, the company is drawing attention to a process risk in cell therapy development related to how and when genomic integrity is evaluated. The post suggests that many programs test genomic stability only once a cell line is ready for manufacturing, even though genomic changes can arise during gene editing, clonal selection, and subsequent cell expansion.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights that testing only at the end of development can make it harder to pinpoint when genomic events occurred or how pervasive they are in the cell population. It further suggests that earlier and repeated genomic integrity analysis may help identify risks sooner, potentially reducing costly downstream failures and improving the reliability of cell therapy pipelines.
For investors, this focus on continuous genomic monitoring points to a market need for more sophisticated analytical tools and services across the cell therapy value chain. If KROMATID’s capabilities align with these requirements, the company could benefit from growing demand among biopharma developers seeking to de-risk programs, which may support recurring revenue opportunities and strengthen its competitive position in advanced therapies analytics.